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Resilience of S309 and AZD7442 monoclonal
antibody treatments against infection by SARSCoV-2 Omicron lineage strains
James Brett Case 1, Samantha Mackin1,2, John M. Errico 2, Zhenlu Chong1, Emily A. Madden 1,
Bradley Whitener1, Barbara Guarino3, Michael A. Schmid 3, Kim Rosenthal4, Kuishu Ren4, Ha V. Dang
Gyorgy Snell5, Ana Jung2, Lindsay Droit2, Scott A. Handley 2, Peter J. Halfmann 6, Yoshihiro Kawaoka
James E. Crowe Jr. 9,10,11, Daved H. Fremont 2,12,13, Herbert W. Virgin 2,5,14, Yueh-Ming Loo 4,
Mark T. Esser 4, Lisa A. Purcell5, Davide Corti 3 & Michael S. Diamond 1,2,12,15,16 ✉

5,
6,7,8,

Omicron variant strains encode large numbers of changes in the spike protein compared to
historical SARS-CoV-2 isolates. Although in vitro studies have suggested that several
monoclonal antibody therapies lose neutralizing activity against Omicron variants, the effects
in vivo remain largely unknown. Here, we report on the protective efﬁcacy against three SARSCoV-2 Omicron lineage strains (BA.1, BA.1.1, and BA.2) of two monoclonal antibody therapeutics (S309 [Vir Biotechnology] monotherapy and AZD7442 [AstraZeneca] combination), which correspond to ones used to treat or prevent SARS-CoV-2 infections in humans.
Despite losses in neutralization potency in cell culture, S309 or AZD7442 treatments reduced
BA.1, BA.1.1, and BA.2 lung infection in susceptible mice that express human ACE2 (K18hACE2) in prophylactic and therapeutic settings. Correlation analyses between in vitro neutralizing activity and reductions in viral burden in K18-hACE2 or human FcγR transgenic mice
suggest that S309 and AZD7442 have different mechanisms of protection against Omicron
variants, with S309 utilizing Fc effector function interactions and AZD7442 acting principally
by direct neutralization. Our data in mice demonstrate the resilience of S309 and AZD7442
mAbs against emerging SARS-CoV-2 variant strains and provide insight into the relationship
between loss of antibody neutralization potency and retained protection in vivo.
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evere acute respiratory syndrome coronavirus 2 (SARSCoV-2) variant strains continue to emerge and spread
globally despite currently employed countermeasures and
public health mandates. Since late 2020, variants of concern
(VOC) and interest (VOI) have arisen due to continued SARSCoV-2 evolution. Many variants contain substitutions in the
N-terminal domain (NTD) and the receptor binding motif
(RBM) of the receptor binding domain (RBD). Omicron lineage
variants containing the largest numbers of spike protein changes
described so far have emerged, spread globally, and become
dominant. Moreover, cell-based studies suggest that the neutralizing activity of many monoclonal antibodies (mAbs) with
Emergency Use Authorization (EUA) status or in advanced
clinical development is diminished or abolished against Omicron
lineage strains1–4. However, the effect of mutations that compromise antibody neutralization on their efﬁcacy in vivo against
SARS-CoV-2 remains less clear. Indeed, for some classes of
broadly neutralizing mAbs against inﬂuenza5,6 and Ebola7,8
viruses, there is no strict correlation between neutralizing activity
in vitro and protection in animal models.
Here, using mAbs that are currently in use to prevent or treat
SARS-CoV-2 infection, we evaluate how the antigenic shift in
Omicron viruses affects neutralization in cells and protection in
mice. Despite some losses in neutralization potency against
Omicron strains, we show that S309 and AZD7442 reduce viral
burden and lung inﬂammation and thus retain appreciable
in vivo activity against the Omicron variants tested. Correlation
analyses between in vitro neutralization activity and in vivo
reductions in lung infection suggest differing mechanisms of
action for S309 and AZD7442, which we establish using genetic
mAb variants and in vitro and in vivo assays.
Results
MAb neutralization against Omicron lineage viruses. We
analyzed the substitutions in the RBDs of BA.1 (B.1.1.529),
BA.1.1 (B.1.1.529 R346K), and BA.2 strains (Fig. 1a, Supplementary Fig. 1) in the context of the structurally-deﬁned binding
epitopes of S309, a cross-reactive SARS-CoV mAb and the parent
of sotrovimab [VIR-7831], and AZD8895 (tixagevimab) and
AZD1061 (cilgavimab), two mAbs that together (AZD7442) form
the clinically-used Evusheld combination treatment (Fig. 1b–e,
Supplementary Fig. 1). S309 binds a conserved epitope on the
RBD that is spatially distinct from the RBM9 and the AZD8895
and AZD1061 antibodies bind non-overlapping RBM epitopes10.
Across Omicron lineage strains, substitutions at several antibody
contact residues have occurred (S309: G339D, R346K, N440K;
AZD8895: K417N, S477N, T478K, E484A, Q493R; AZD1061:
R346K, N440K, E484A, Q493R).
Because of these sequence changes, we assessed the neutralizing
activity of S309, AZD8895, AZD1061, and AZD7442 against
BA.1, BA.1.1, and BA.2 viruses in Vero-TMPRSS2 cells. For these
studies, we used mAbs that correspond to the products in clinical
use which have Fc modiﬁcations: S309-LS [M428L/N434S],
AZD8895-YTE/TM [M252Y/S254T/T256E and L234F/L235E/
P331S], AZD1061-YTE/TM, and AZD7442-YTE/TM. The LS
and YTE Fc substitutions result in extended antibody half-life in
humans, and the TM changes reduce Fc effector functions11.
Compared to the historical WA1/2020 D614G strain (hereafter
D614G), antibody incubation with BA.1 was associated with 2.5fold (S309-LS), 25-fold (AZD7442-YTE/TM), 118-fold
(AZD8895-YTE/TM), and 206-fold (AZD1061-YTE/TM) reductions in neutralization potency (Fig. 1f–o), which agree with
experiments with authentic or pseudotyped SARS-CoV-21–4.
Some differences were observed with BA.1.1: whereas S309-LS
and AZD8895-YTE/TM were only slightly less effective against
2

BA.1.1 compared to BA.1, the neutralizing activity of AZD1061YTE/TM was reduced by almost 1,700-fold. Despite the decrease
in activity of the AZD1061-YTE/TM component, the AZD7442YTE/TM combination still showed inhibitory activity against
BA.1.1 with a 176-fold reduction compared to D614G. Whereas
small (no change to 5-fold) reductions in neutralization activity
were observed with AZD1061-YTE/TM and AZD7442-YTE/TM
against BA.2, larger reductions (32- and 68-fold) were observed
for S309-LS and AZD8895-YTE/TM compared to D614G. We
also observed lower binding afﬁnity of S309, AZD8895, or
AZD1061 Fab fragments to Omicron lineage RBDs, with the
exception of AZD1061 and BA.2 (Supplementary Fig. 2, 3), which
is consistent with neutralization trends for each mAb. Overall,
these data demonstrate that S309 retains potency against BA.1
and BA.1.1 strains but has less in vitro neutralizing activity
against BA.2, and the AZD7442 combination shows reduced yet
residual activity against strains from all three Omicron lineages.
MAb protection in vivo against Omicron viruses. Because S309
and AZD7442 mAbs might act in vivo by a combination of
mechanisms that are not fully reﬂected by in vitro neutralization
potency assays, we evaluated the effects of the mutations observed
in BA.1, BA.1.1 and BA.2 on efﬁcacy in animals. For these studies,
we used S309-LS and a different form of AZD7442, which contained only the TM substitutions and not the YTE modiﬁcation
but retains equivalent neutralizing activity2. Although the YTE
modiﬁcation promotes antibody recycling to confer extended
antibody half-life in humans and non-human primates, it accelerates antibody elimination in rodents12. To assess the efﬁcacy of
S309-LS and AZD7442-TM in vivo, we administered a single
200 μg (~10 mg/kg total) mAb dose to K18-hACE2 transgenic
mice by intraperitoneal injection one day prior to intranasal
inoculation with BA.1, BA.1.1, or BA.2 strains. The clinical dosing
in humans for sotrovimab is 500 mg and for AZD7442 is 300 mg
of tixagevimab (AZD8895) + 300 mg of cilgavimab (AZD1061).
Although Omicron lineage viruses are less pathogenic in mice,
they still replicate to high levels in the lungs of K18-hACE2
mice13. Nonetheless, as preliminary studies suggested slightly
different kinetics of replication and spread in mice, we harvested
samples at 7 dpi for BA.1 and BA.1.1 and 6 dpi for BA.213. In
BA.1 and BA.1.1-infected mice, S309-LS mAb reduced viral
burden in the lung, nasal turbinates, and nasal washes at 7 dpi
compared to isotype mAb-control treated mice (Fig. 2a–d).
However, control of infection by S309-LS, as judged by viral RNA
levels, was less efﬁcient against BA.1 (182-fold reduction) and
BA.1.1 (39-fold reduction) viruses than against D614G
( >500,000-fold reduction) (Supplementary Table 1). Despite the
diminished neutralizing activity against BA.2 in vitro, S309-LS
treatment reduced viral RNA levels in the lungs of BA.2-infected
mice substantially (742-fold reduction) (Fig. 2a, b, Supplementary
Table 1). Protection by S309-LS was not observed in the nasal
turbinates or nasal washes of mice challenged with BA.2 (Fig. 2c,
d), in part due to the low and variable levels of infection with this
variant. AZD7442-TM treatment differentially reduced viral
burden in the lungs of mice against D614G (>400,000-fold
reduction in viral RNA), BA.1 (92-fold reduction in viral RNA),
BA.1.1 (4-fold reduction in viral RNA), and BA.2 (>100,000-fold
reduction in viral RNA) (Fig. 2e, f, Supplementary Table 1).
Protection in the upper respiratory tract was less consistent, as
AZD7442-TM treatment lowered viral RNA levels in the nasal
washes of D614G and BA.1-infected mice but not in BA.1.1 or
BA.2-infected mice and failed to reduce D614G, BA.1, BA.1.1, or
BA.2 infection in the nasal turbinates (Fig. 2g, h).
As independent metrics of mAb protection, we measured
cytokine and chemokine levels in lung homogenates and
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analyzed lung sections for pathology from S309-LS and
AZD7442-TM treated animals infected with Omicron variant
strains (Fig. 2i, j, Supplementary Figs. 4–6). All infected K18hACE2 mice receiving isotype control mAbs had increased
expression levels of several pro-inﬂammatory cytokines and
chemokines such as G-CSF, GM-CSF, IFN-γ, IL-1β, IL-6,
CXCL-10, CCL-2, and CCL-4 when compared to uninfected
mice. In contrast, mice treated with AZD7442-TM mAbs and

ARTICLE

infected with BA.1 or BA.2 but not BA.1.1. showed reduced
levels of pro-inﬂammatory cytokines and chemokines, which is
consistent with effects on viral burden (Fig. 2e, f). Compared to
the isotype controls, mice treated with S309-LS had lower levels
of cytokines and chemokines in lung homogenates after
infection with all three Omicron variants, although the
protection against BA.2-induced inﬂammation was less than
against BA.1. or BA.1.1.
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Fig. 1 Neutralization of Omicron lineage strains by mAbs. a One protomer of the SARS-CoV-2 spike trimer (PDB: 7C2L) is depicted with BA.2 variant
amino acid substitutions labelled and shown as red spheres. The N-terminal domain (NTD), RBD, RBM, and S2 are colored in yellow, green, magenta, and
blue, respectively. All mutated residues in the BA.2 RBD relative to WA1/2020 are indicated in b, and the BA.2 RBD bound by mAbs S309 (orange, PDB:
6WPS) (b), AZD8895 (green, PDB: 7L7D) (c), and AZD1061 (purple, PDB:7L7E) (d) are shown. BA.2 mutations in the respective epitopes of each mAb are
shaded red, whereas those outside the epitope are shaded green. e Multiple sequence alignment showing the epitope footprints of each mAb on the SARSCoV-2 RBD (orange, S309; green, AZD8895; purple, AZD1061). The WA1/2020 RBD is shown in the last row with relative variant sequence changes
indicated. Red circles below the sequence alignment indicate hACE2 contact residues on the SARS-CoV-2 RBD43. Structural analysis and depictions were
generated using UCSF ChimeraX44. f–i Neutralization curves in Vero-TMPRSS2 cells with the indicated SARS-CoV-2 strain and mAb. The average of three
to four experiments performed in technical duplicate are shown. j–m Comparison of EC50 values for the indicated mAb against D614G, BA.1, BA.1.1, and
BA.2 viruses. Data are the average of three experiments, error bars indicate standard error of the mean (SEM), and the dashed line indicates the upper limit
of detection (one-way ANOVA with Dunnett’s test; ns, not signiﬁcant, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001). n Summary of the EC50 values
for each mAb against the indicated SARS-CoV-2 strain. o Summary of the fold-change in EC50 values for each mAb against the indicated Omicron strain
relative to SARS-CoV-2 D614G. Source data are provided as a Source Data ﬁle.

Histopathological analysis of lungs from isotype-treated, but
not S309-LS- or AZD7442-TM-treated, D614G-infected K18hACE2 mice at 7 dpi showed evidence of pneumonia with
immune cell inﬁltration, alveolar space consolidation, and edema
(Supplementary Fig. 6). Although infection of rodents with BA.1,
BA.1.1, or BA.2 strains results in less pathogenesis than D614G
strains13–16, focal pneumonia still was observed in isotype control
mAb-treated, Omicron strain-infected K18-hACE2 mice. In
comparison, S309-LS or AZD7442-TM treatment prevented
immune cell inﬁltration and airspace consolidation. Overall,
these experiments suggest that despite losses in neutralizing
potency in cell culture, S309-LS or AZD7442-TM treatment can
limit inﬂammation and pathogenesis in the lung caused by
Omicron variants.
We next evaluated whether the differences in neutralizing
activity of S309-LS and AZD7442-YTE/TM correlated with
changes in lung viral RNA levels after infection with the three
Omicron strains. The change in AZD7442-YTE/TM neutralizing
activity associated directly with the differences in lung viral burden
of each Omicron variant (Fig. 2k). This relationship is consistent
with its likely mechanism of action, virus neutralization and
inhibition of entry17,18. The AZD7442-TM version we used, like
the clinical drug tixagevimab + cilgavimab, encodes for modiﬁcations in the constant region of the mAb heavy chains that
profoundly decrease binding to Fc-gamma receptors (FcγRs) and
complement components (ref. 19 and Fig. 3a). In comparison, for
S309-LS, a similar direct correlation between changes in neutralization potency in vitro and reductions in viral burden in vivo was
not observed (Fig. 2l), indicating a possible additional protective
mechanism beyond virus neutralization.
S309-LS employs Fc effector functions to protect against SARSCoV-2 variants. To evaluate a potential role for Fc effector functions in S309 mAb-mediated protection against Omicron strains,
we engineered loss-of-function GRLR mutations (G236R, L328R)
into the Fc domain of the human IgG1 heavy chain of S309; these
substitutions eliminate antibody binding to FcγRs11. Introduction
of the GRLR mutations abrogated binding to hFcγRI, hFcγRIIIa,
and mFcγRIV, as expected (Fig. 3a) but did not affect neutralization of the SARS-CoV-2 strains (Supplementary Fig. 7). Next, we
compared VIR-7831 (the clinical form of S309-LS) and S309-GRLR
in an in vitro antibody-dependent cell cytotoxicity (ADCC) assay.
When target cells expressing similar levels of Wuhan-D614, BA.1,
or BA.2 spike proteins on the cell surface were incubated with VIR7831 mAb, we observed some reductions in binding to Omicron
spike proteins compared to mAb S2X324 (Fig. 3b, c), an antibody
that retains neutralizing activity against BA.1, BA.1.1, and BA.2 and
engages a distinct epitope in the RBM20. Despite the differences in
binding, target cells expressing Wuhan-D614, BA.1, or BA.2 spike
proteins were lysed efﬁciently by primary natural killer (NK) cells
4

(antibody-dependent cellular cytotoxicity, ADCC) isolated from
four donors by VIR-7831 but not by S309-GRLR (Fig. 3d, e, Supplementary Fig. 8a). Similarly, primary CD14+ monocytes isolated
from ﬁve donors mediated comparable antibody-dependent cellular phagocytosis (ADCP) of target cells expressing Wuhan-D614,
BA.1, or BA.2 spike proteins by VIR-7831 but not by S309-GRLR
(Fig. 3f, g, Supplementary Fig. 8b, c).
To evaluate the role of effector functions in vivo in S309-LS mAbmediated protection against Omicron variant strains, we treated
K18-hACE2 mice with a single 200 μg (~10 mg/kg total) dose of
S309-GRLR mAb by intraperitoneal injection one day prior to
intranasal inoculation with D614G, BA.1, or BA.2 strains. At 6
(BA.2) or 7 (D614G and BA.1) dpi, viral RNA levels in the lungs,
nasal turbinates, and nasal washes were measured (Fig. 4a–c,
Supplementary Table 1). Although S309-GRLR treatment reduced
viral burden in the lung (6-fold) and nasal turbinates (10-fold) of
D614G-infected mice, reductions were modest compared to mice
receiving S309-LS (>500,000-fold and 230-fold respectively; see
Fig. 2a, c, Supplementary Table 1); moreover, S309-GRLR did not
limit infection by BA.1 and BA.2 strains in the tissues tested. Indeed,
similarly high levels of pro-inﬂammatory cytokine and chemokine
were measured in the lung homogenates of S309-GRLR and isotype
control mAb-treated mice infected with D614G and BA.1 strains
(Fig. 4d, Supplementary Fig. 9). To corroborate these ﬁndings, we
treated hFcγR transgenic C57BL/6 mice21 (hFcγR Tg) with a single
3 mg/kg dose of S309-LS or S309-GRLR mAbs one day prior to
inoculation with a SARS-CoV-2 Beta (B.1.351) isolate; we used the
Beta isolate for these studies because Omicron strains replicate
poorly in conventional C57BL/6 mice lacking expression of
hACE213. At 2 or 4 dpi, S309-LS mAb-treated hFcγR Tg mice
showed markedly reduced levels of viral RNA (15 to 47 fold or
infectious virus 81- to 292-fold) in the lung compared to the isotype
control mAb-treated mice, whereas animals administered S309GRLR showed smaller (3-fold) differences, most of which did not
attain statistical signiﬁcance (Fig. 4e, f, Supplementary Table 1).
Collectively, these data suggest that the protection mediated by S309LS mAb in vivo relies to a large extent on Fc effector functions and
engagement of FcγRs.
We next evaluated the therapeutic potential of S309-LS and
AZD7442-TM against D614G and each of the Omicron variants
by administering mAbs at one day post-virus inoculation. Both
S309-LS and AZD7442-TM reduced viral RNA titers in the lungs
and nasal turbinates (Fig. 4g, h and Supplementary Table 1)
against all variants tested, with the one exception (AZD7442-TM
versus BA.1.1 in the nasal turbinates). Moreover, therapeutic
administration of S309-LS and AZD7442-TM reduced viral RNA
levels in the nasal washes of D614G, BA.1, and BA.1.1-infected,
but not BA.2-infected, mice (Fig. 4i). Overall, these data establish
that S309-LS and AZD7442-TM have post-exposure therapeutic
activity against multiple Omicron variant strains.
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Discussion
Due to the continued emergence of SARS-CoV-2 variants
encoding an increasing number of amino acid changes in the
spike protein, antibody countermeasure efﬁcacy requires continued monitoring. When the BA.1 Omicron virus emerged in
late 2021, ﬁve mAb therapies were in late-stage clinical

development or had acquired EUA status. In vitro assays with
pseudoviruses1 and authentic viruses2 established that mAb
therapies from Regeneron (REGN10933 and REGN10987), Lilly
(LY-CoV555 and LY-CoV016), and Celltrion (CT-P59) showed a
complete loss in neutralizing activity against BA.1. Subsequent
experiments in K18-hACE2 mice conﬁrmed that the REGN-

NATURE COMMUNICATIONS | (2022)13:3824 | https://doi.org/10.1038/s41467-022-31615-7 | www.nature.com/naturecommunications

5

ARTICLE

NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-022-31615-7

Fig. 2 Antibody protection against Omicron variants in K18-hACE2 mice. a–j Eight-week-old female K18-hACE2 mice received 200 μg (about 10 mg/kg)
of the indicated mAb treatment by intraperitoneal injection one day before intranasal inoculation with 103 FFU of the indicated SARS-CoV-2 strain. Tissues
were collected at six (BA.2) or seven days (all other strains) after inoculation. Viral RNA levels in the lungs (a, e), nasal turbinates (c, g), and nasal washes
(d, h) were determined by RT-qPCR, and infectious virus in the lungs (b, f) was assayed by plaque assay (lines indicate median ± SEM.; n = 6–8 mice per
group, two experiments; Two-tailed Mann-Whitney test between isotype and mAb treatment; ns, not signiﬁcant; *P < 0.05, **P < 0.01, ***P < 0.001).
i, j Heat map of cytokine and chemokine protein expression levels in lung homogenates from the indicated groups. Data are presented as log2-transformed
fold-change over naive mice. Blue, reduction; red, increase. k, l, Correlation analysis. The fold-change in EC50 value of AZD7442-YTE/TM (k) and S309-LS
(l) for D614G and each Omicron variant strain are plotted on the x-axis. The fold-change in lung viral RNA titer between the respective isotype or mAbtreated groups against each Omicron variant strain are plotted on the y-axis. Best-ﬁt lines were calculated using a simple linear regression. Two-tailed
Pearson correlation was used to calculate the R2 and P values indicated within each panel. Source data are provided as a Source Data ﬁle.

COV2 mAb cocktail completely lost its efﬁcacy against the BA.1
variant22. More recently, an additional antibody (LY-CoV1404,
bebtelovimab), which shows considerable neutralization activity
against a range of SARS-CoV-2 strains, received EUA status23,
although protection data in vivo against VOC, including Omicron, has not yet been published. Our data suggest that both
neutralizing and Fc effector activities of mAb therapies should be
considered when making recommendations about dosing and
usage against emerging SARS-CoV-2 variants.
We compared the in vitro neutralizing activity and in vivo efﬁcacy
of S309 (parent mAb of sotrovimab) and AZD7442 (tixagevimab + cilgavimab) that correspond to the clinically-used products. Our study establishes the utility of S309 and AZD7442 mAbs
against highly divergent SARS-CoV-2 variants. Despite losses in
neutralization potency against BA.1, BA.1.1, and BA.2 strains, S309LS and AZD7442-TM reduced viral burden and pro-inﬂammatory
cytokine levels in the lungs of K18-hACE2 mice, albeit with some
differences in activity and mechanisms of action. Although
AZD7442-TM had a limited protective effect on viral burden in the
nasal washes and nasal turbinates of infected mice, this was not
entirely unexpected, as studies with the parental mAbs COV2-2196
and COV2-2130 showed less protection in nasal washes than lungs
against multiple SARS-CoV-2 VOC24. Moreover, studies in nonhuman primates with anti-SARS-CoV-2 human mAbs showed the
concentrations in nasopharyngeal washes are approximately 0.1% of
those found in the serum25, which likely explains their diminished
beneﬁt in this tissue compartment.
We also assessed whether the reductions in mAb neutralization
potency against Omicron variant strains correlated with the
observed changes in viral burden. For AZD7442-TM, which
contains L234F/L235E/P331S modiﬁcations that abolish Fc
receptor engagement11 and were introduced to decrease the
potential risk of antibody-dependent enhancement of disease18,
antibody-mediated reductions in viral titer correlated directly
with neutralization activity against Omicron variant strains; thus,
neutralization is likely the key protective mechanism for these
RBM-speciﬁc mAbs. For S309-LS, which only contains half-life
extending M428L/N434S modiﬁcations in the human IgG1 Fc
domain, and exhibits Fc effector functions including ADCC and
ADCP9, changes in neutralization potency did not linearly relate
to changes in lung viral titer. S309-LS mAb treatment still conferred signiﬁcant protection in the lungs of mice infected with
BA.2 despite a substantial loss in neutralizing activity. Because of
these results, we evaluated the contributions of Fc effector functions in protection in mice using S309-GRLR, which has G236R/
L328R mutations in the Fc domain that abrogate binding to
FcγRs11. We observed that intact S309-LS but not S309-GRLR
mAb protected K18-hACE2 and hFcγR Tg mice against SARSCoV-2 variant strains. These results are consistent with prior
studies showing a beneﬁcial role of Fc-effector functions in
antibody mediated protection in mice and hamsters26–30, and
may explain why mAbs with markedly different in vitro neutralization potencies against SARS-CoV-2 strains show similar
6

protective activity in animals (https://opendata.ncats.nih.gov/
covid19/animal). Furthermore, they also demonstrate that for
some mAbs, Fc effector functions can compensate for losses in
neutralization potency against SARS-CoV-2 variants and act as a
protective mechanism in vivo. Thus, effector functions can contribute to resilience of some mAbs against Omicron and other
VOC31,32. We speculate that the stoichiometric threshold and
antibody occupancy requirements for Fc effector function activity
may be lower than for virion neutralization33; if so, this property
might clarify how antibodies with reduced neutralizing potency
against VOC that still bind spike protein on the virion or surface
of infected cells retain protective activity in vivo. Alternatively,
potential differences in spike expression on the surface of Omicron (BA.1, BA.1.1, and BA.2)-infected cells could further modulate S309-Fc-mediated effector function activity.
We note several limitations of our study: (a) Female K18-hACE2
mice were used to allow for group caging. Follow-up experiments
in male mice to conﬁrm and extend these results are needed. (b)
The BA.1, BA.1.1., and BA.2 viruses are less pathogenic in mice
than the D614G virus13–16. This could lead to an overestimation of
protection compared to other more virulent strains in mice. (c) The
relationship between initial viral dosing and antibody protection
against Omicron variants was not explored. (d) Several experiments were performed in transgenic mice that over-express human
ACE2 receptors. High levels of cellular hACE2 can diminish the
neutralizing activity of mAbs that bind non-RBM sites of the
SARS-CoV-2 spike34,35. Thus, studies in hACE2-transgenic mice
could underestimate the efﬁcacy of mAbs binding outside of the
RBM. Challenge studies in other animal models and ultimately
humans will be required for corroboration. (e) We did not assess
mAb efﬁcacy against the newest emerging Omicron variants
including BA.2.11, BA.2.12.1, BA.4, or BA.5, which recently were
linked to antibody escape in pseudovirus-based neutralization
assays36,37. In vitro and in vivo evaluation of S309 (sotrovimab)
and AZD7442 (tixagevimab + cilgavimab) against these strains
using authentic SARS-CoV-2 viruses are needed. (f) We did not
identify the speciﬁc immune effector cells that mediate the protective Fc-mediated effector responses in vivo. Future studies are
needed to determine the cell types and inﬂammatory mediators
responsible for this mechanism of antibody protection.
Collectively, our data expand on recent in vitro ﬁndings with
BA.1 strains by evaluating the level of protection conferred by
treatment with two EUA mAbs against the three currently
dominant Omicron variants. While S309-LS (and by extension
sotrovimab) and AZD7442-TM (tixagevimab + cilgavimab)
retained inhibitory activity against several Omicron lineage
strains, the impact of shifts in neutralization potency in vitro may
not directly predict dosing in the clinical setting. Finally, our
studies highlight the potential of both mAb neutralization and Fc
effector function mechanisms in protecting against SARS-CoV-2mediated disease and suggest mechanisms of action for withstanding mutations in variant strains that reduce but do not
abrogate mAb binding and neutralization.
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Fig. 3 VIR-7831 binds and instructs effector cells for ADCC and ADCP. a Binding of S309-LS, S309-GRLR, or AZD7442-TM mAbs to hFcγRI, hFcγRIIIa, or
mFcγRIV (two experiments; dotted lines indicate the limit of detection; data are presented as meanvalues ± range). b ExpiCHO-S cells were transiently
transfected with plasmids encoding the indicated SARS-CoV-2 spike protein. 24 to 48 h later, cells were harvested, washed, and stained with the indicated
concentrations of VIR-7831 or S2X324 mAbs to assess binding to the cell surface. Representative histograms from two or three experiments are shown.
c Antibody binding curves for VIR-7831 and S2X324 using the data in b and presented as mean ﬂuorescence intensity (MFI) versus antibody concentration.
d, e ExpiCHO-S cells transiently transfected with Wuhan-1 D614, BA.1, or BA.2 spike proteins were incubated with the indicated concentrations of VIR-7831
or S309-GRLR mAb and mixed with puriﬁed NK cells isolated from healthy donors at a ratio of 1:9 (target:effector). Cell lysis was determined by a lactate
dehydrogenase release assay. Data are presented as mean values ± standard deviations (SD) from one representative of four donors (d). Area under the
curve (AUC) analyses from four NK donors (e) (see Supplementary Fig. 8). f, g ExpiCHO-S cells transiently transfected with Wuhan-1 D614, BA.1, or
BA.2 spike proteins and ﬂuorescently labelled with PKH67 were incubated with the indicated concentrations of VIR-7831 or S309-GRLR mAb and mixed
with PBMCs labelled with CellTrace Violet from healthy donors at a ratio of 1:20 (target:PBMCs). Association of CD14+ monocytes with spike-expressing
target cells (ADCP) was determined by ﬂow cytometry. Data are presented as mean values ± SD from one representative of ﬁve donors (f). AUC analyses
of VIR-7831 and S309-GRLR for each Omicron variant for ﬁve donors (g). e, g Two-tailed Mann-Whitney test between VIR-7831 and S309-GRLR for the
indicated variant; *P < 0.05, **P < 0.01. Source data are provided as a Source Data ﬁle. Gating strategies are shown in Supplementary Fig. 8c.

Methods
Cells. Vero-TMPRSS238 and Vero-hACE2-TMPRRS239 cells were cultured at
37 °C in Dulbecco’s Modiﬁed Eagle medium (DMEM) supplemented with 10%
fetal bovine serum (FBS), 10 mM HEPES pH 7.3, 1 mM sodium pyruvate, 1× nonessential amino acids, and 100 U/ml of penicillin–streptomycin. Vero-TMPRSS2
cells were supplemented with 5 μg/mL of blasticidin. Vero-hACE2-TMPRSS2 cells
were supplemented with 10 µg/mL of puromycin. ExpiCHO-S cells were obtained
from Thermo Fisher Scientiﬁc. All cells routinely tested negative for mycoplasma
using a PCR-based assay.
Viruses. The Beta (B.1.351) and Omicron (BA.1 (R346), BA.1.1 (R346K), and
BA.2) strains were obtained from nasopharyngeal isolates. All virus stocks were

generated in Vero-TMPRSS2 cells and subjected to next-generation sequencing as
described previously39 to conﬁrm the presence and stability of expected substitutions (see Supplementary Table 2). All virus experiments were performed in an
approved biosafety level 3 (BSL-3) facility.
Monoclonal antibody puriﬁcation. The mAbs studied in this paper, S309,
AZD8895, AZD1061, and the AZD7442 cocktail have been described
previously9,18,20.
S309-LS and S309-GRLR were produced in ExpiCHO-S cells and afﬁnitypuriﬁed using HiTrap Protein A columns (GE Healthcare, HiTrap mAb select Xtra
#28-4082-61) followed by buffer exchange to histidine buffer (20 mM histidine, 8%
sucrose, pH 6.0) using HiPrep 26/10 desalting columns. The ﬁnal products were
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Fig. 4 Fc-effector functions and mAb-mediated protection. a–d Eight-week-old female K18-hACE2 mice or (e, f) 12-week-old male hFcγR Tg mice
received a single 10 mg/kg or 3 mg/kg dose respectively, of isotype control, S309-LS or S309-GRLR mAb by intraperitoneal injection one day before
intranasal inoculation with 103 FFU of D614G, BA.1, or BA.2 (a-c) or 105 FFU of Beta (B.1.351) (e, f). Tissues were collected at 2 (B.1.351), 4 (B.1.351), 6
(BA.2), or 7 (D614G and BA.1) dpi. Viral RNA levels in the lungs (a, e, f), nasal turbinates (b), and nasal washes (c) were determined by RT-qPCR, and
infectious virus in the lungs (e, f) was measured by plaque assay. a-c, e, f lines indicate median ± SEM.; a-c and e, f n = 8 and 10 mice per group,
respectively; two experiments; a-c Two-tailed Mann-Whitney test between isotype and mAb treatment; ns, not signiﬁcant; **P < 0.01, ***P < 0.001 e, f oneway ANOVA with Tukey’s multiple comparisons test; ns, not signiﬁcant; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001). d Heat map of cytokine and
chemokine protein expression levels in lung homogenates from the indicated groups. Data are presented as log2-transformed fold-change over naive mice.
Blue, reduction; red, increase. S309-LS data in Fig. 2i is included for comparison. g–i Eight-week-old female K18-hACE2 mice were inoculated with 103 FFU
of the indicated SARS-CoV-2 strain by intranasal administration one day before receiving a single 30 mg/kg dose of S309-LS or AZD7442-TM mAb by
intraperitoneal injection. Tissues were collected at 6 (BA.2) or 7 (all other strains) dpi. Viral RNA levels in the lungs (g), nasal turbinates (h), and nasal
washes (i) were determined by RT-qPCR. g–i lines indicate median ± SEM; n = 8 mice per group; two experiments; Kruskal-Wallis test between isotype
control and each mAb treatment with Dunn’s multiple comparisons test; ns, not signiﬁcant; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Source data
are provided as a Source Data ﬁle.
sterilized after passage through 0.22 μm ﬁlters and stored at 4 °C. VIR-7831
(clinical lead variant of S309-LS) was produced at WuXi Biologics.
AZD8895 and AZD1061 mAbs were cloned into mammalian expression
vectors and expressed as IgG1 constructs with the TM (L234F/L235E/P331S) Fc
modiﬁcation with or without a second YTE (M252Y/S254T/T256E) modiﬁcation
to extend half-life in humans. MAbs were expressed in 293 F cells after
transfection with 293fectin (Thermo Fisher Scientiﬁc) and isolated from
supernatants by afﬁnity chromatography using Protein A or Protein G columns
(GE Healthcare). MAbs were eluted with 0.1 M glycine at low pH and dialyzed
into PBS.

Mouse experiments. Animal studies were carried out in accordance with the
recommendations in the Guide for the Care and Use of Laboratory Animals of the
National Institutes of Health. The protocols were approved by the Institutional
Animal Care and Use Committee at the Washington University School of Medicine
(assurance number A3381–01). Virus inoculations were performed under
8

anesthesia that was induced and maintained with ketamine hydrochloride and
xylazine, and all efforts were made to minimize animal suffering.
Heterozygous K18-hACE2 C57BL/6 J mice (strain: 2B6.Cg-Tg(K18-ACE2)
2Prlmn/J) were obtained from The Jackson Laboratory. Human FcγR Tg mice21
(FcγRα−/−/hFcγRI+/hFcγRIIAR131+/hFcγRIIB+/hFcγRIIIAF158+/hFcγRIIIB+)
were a generous gift (J. Ravetch, Rockefeller University) and bred at Washington
University. All animals were housed in groups of 3 to 5 and fed standard chow
diets. The photoperiod was 12 h on:12 h off dark/light cycle. The ambient animal
room temperature was 70° F, controlled within ±2° and the room humidity was
50%, controlled within ±5%.
For experiments with K18-hACE2 mice, eight- to ten-week-old female mice were
administered the indicated doses of the respective SARS-CoV-2 strains (see Figure
legends) by intranasal administration. For hFcγR Tg mouse experiments, 12-weekold male mice were administered 105 FFU of a Beta (B.1.351) isolate by intranasal
administration. In vivo studies were not blinded, and mice were randomly assigned
to treatment groups. No sample-size calculations were performed to power each
study. Instead, sample sizes were determined based on prior in vivo virus challenge
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experiments. Mice were administered the indicated mAb dose by intraperitoneal
injection one day before or after intranasal inoculation with the indicated SARSCoV-2 strain. AZD7442-TM (lacking the YTE modiﬁcation that accelerates antibody
elimination in rodents) was used in mouse studies.
Focus reduction neutralization test. Serial dilutions of mAbs were incubated with
102 focus-forming units (FFU) of different strains or variants of SARS-CoV-2 for
1 h at 37 °C. Antibody-virus complexes were added to Vero-TMPRSS2 cell
monolayers in 96-well plates and incubated at 37 °C for 1 h. Subsequently, cells
were overlaid with 1% (w/v) methylcellulose in MEM. Plates were harvested
48–72 h later by removing overlays and ﬁxing with 4% PFA in PBS for 20 min at
room temperature. Plates were washed and incubated with an oligoclonal pool of
SARS2-2, SARS2–11, SARS2–16, SARS2–31, SARS2–38, SARS2–57, and
SARS2–7140. Plates with Omicron variant strains were additionally incubated with
CR3022 and a pool of anti-SARS-CoV-2 mAbs that cross-react with SARS-CoV41.
Subsequently, samples were incubated with HRP-conjugated goat anti-mouse IgG
(Sigma, 12–349) and HRP-conjugated goat anti-human IgG (Sigma, A6029) in PBS
supplemented with 0.1% saponin and 0.1% bovine serum albumin. SARS-CoV-2infected cell foci were visualized using TrueBlue peroxidase substrate (KPL) and
quantitated on an ImmunoSpot microanalyzer (Cellular Technologies).
Measurement of viral RNA levels. Tissues were weighed and homogenized with
zirconia beads in a MagNA Lyser instrument (Roche Life Science) in 1 mL of DMEM
medium supplemented with 2% heat-inactivated FBS. Tissue homogenates were
clariﬁed by centrifugation at approximately 10,000 × g for 5 min and stored at
−80 °C. RNA was extracted using the MagMax mirVana Total RNA isolation kit
(Thermo Fisher Scientiﬁc) on the Kingﬁsher Flex extraction robot (Thermo Fisher
Scientiﬁc). RNA was reverse transcribed and ampliﬁed using the TaqMan RNA-toCT 1-Step Kit (Thermo Fisher Scientiﬁc). Reverse transcription was carried out at
48 °C for 15 min followed by 2 min at 95 °C. Ampliﬁcation was accomplished over 50
cycles as follows: 95 °C for 15 s and 60 °C for 1 min. Copies of SARS-CoV-2 N gene
RNA in samples were determined using a previously published assay42. Brieﬂy, a
TaqMan assay was designed to target a highly conserved region of the N gene
(Forward primer: ATGCTGCAATCGTGCTACAA; Reverse primer:
GACTGCCGCCTCTGCTC; Probe: /56-FAM/TCAAGGAAC/ZEN/AACATTGCCAA/3IABkFQ/). This region was included in an RNA standard to allow for copy
number determination down to 10 copies per reaction. The reaction mixture contained ﬁnal concentrations of primers and probe of 500 and 100 nM, respectively.
Viral plaque assay. Vero-TMPRSS2-hACE2 cells were seeded at a density of
1 × 105 cells per well in 24-well tissue culture plates. The following day, medium
was removed and replaced with 200 μL of material to be titrated diluted serially in
DMEM supplemented with 2% FBS. One hour later, 1 mL of methylcellulose
overlay was added. Plates were incubated for 72 h, then ﬁxed with 4% paraformaldehyde (ﬁnal concentration) in PBS for 20 min. Plates were stained with
0.05% (w/v) crystal violet in 20% methanol and washed twice with distilled,
deionized water.
Transient expression of recombinant SARS-CoV-2 protein and ﬂow cytometry. ExpiCHO-S cells were seeded at 6 × 106 cells/mL in a volume of 5 mL in a
50 mL bioreactor. The following day, cells were transfected with SARS-CoV-2 spike
glycoprotein-encoding pcDNA3.1(+) plasmids (BetaCoV/Wuhan-Hu-1/2019,
accession number MN908947, Wuhan D614; Omicron BA.1 and BA.2 generated
by overlap PCR mutagenesis of the Wuhan D614 plasmid) harboring the Δ19
C-terminal truncation27. Spike encoding plasmids were diluted in cold OptiPRO
SFM (Life Technologies, 12309-050), mixed with ExpiFectamine CHO Reagent
(Life Technologies, A29130) and added to cells. Transfected cells were then
incubated at 37˚C with 8% CO2 with an orbital shaking speed of 250 RPM (orbital
diameter of 25 mm) for 24 to 48 h. Transiently transfected ExpiCHO-S cells were
harvested and washed twice in wash buffer (PBS 2% FBS, 2 mM EDTA). Cells were
counted and distributed into round bottom 96-well plates (Corning, 3799) and
incubated with serial dilutions of mAb starting at 10 μg/mL. Alexa Fluor647labelled Goat Anti-human IgG secondary Ab (Jackson ImmunoResearch,
109–606–098) was prepared at 2 μg/mL and added onto cells after two washing
steps. Cells were then washed twice and resuspended in wash buffer for data
acquisition at ZE5 cytometer (BioRad).
Fc-mediated effector functions. Primary cells were collected from healthy human
donors with informed consent and authorization via the Comitato Etico Canton
Ticino (Switzerland). ADCC assays were performed using ExpiCHO-S cells transiently transfected with SARS-CoV-2 spike glycoproteins (Wuhan D614, BA.1 or
BA.2) as targets. NK cells were isolated from fresh blood of healthy donors using
the MACSxpress NK Isolation Kit (Miltenyi Biotec, cat. no. 130-098-185). Target
cells were incubated with titrated concentrations of mAbs for 10 min and then with
primary human NK cells at an effector:target ratio of 9:1. ADCC was measured
using LDH release assay (Cytotoxicity Detection Kit (LDH) (Roche; cat. no.
11644793001) after 4 h incubation at 37˚C.
ADCP assays were performed using ExpiCHO-S cells transiently transfected
with SARS-CoV-2 spike glycoproteins (Wuhan D614, BA.1, or BA.2) and labelled
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with PKH67 (Sigma Aldrich) as targets. PMBCs from healthy donors were labelled
with CellTrace Violet (Invitrogen) and used as source of phagocytic effector cells.
Target cells (1000 per well) were incubated with titrated concentrations of mAbs
for 10 min and then mixed with PBMCs (200,000 per well). The next day, cells
were stained with APC-labelled anti-CD14 mAb (BD Pharmingen), BV605-labelled
anti-CD16 mAb (BioLegend), BV711-labelled anti-CD19 mAb (BioLegend),
PerCP/Cy5.5-labelled anti-CD3 mAb (BioLegend), APC/Cy7-labelled anti-CD56
mAb (BioLegend) for the identiﬁcation of CD14+ monocytes. After 20 min, cells
were washed and ﬁxed with 4% paraformaldehyde before acquisition on a ZE5 Cell
Analyzer (Bio-Rad). Data were analyzed using FlowJo v10 software. The % ADCP
was calculated as % of monocytes (CD3- CD19- CD14+ cells) positive for PKH67.

MAb afﬁnity measurements. (a) S309. SARS-CoV-2 RBD constructs contain
residues 328–531 of the spike protein from GenBank NC_045512.2 with an
N-terminal signal peptide and a C-terminal 8xHis-AviTag. Proteins were expressed
in Expi293F cells (Thermo Fisher Scientiﬁc) at 37 °C and 8% CO2. Transfections
were performed using the ExpiFectamine 293 Transfection Kit (Thermo Fisher
Scientiﬁc). Cell culture supernatants were harvested ﬁve days after transfection by
spinning at 4,000 × g for 20 min. Supernatants were then ﬁltered through a 0.22 µm
ﬁlter and supplemented with 10× PBS to a ﬁnal concentration of 2.5× PBS
(342.5 mM NaCl, 6.75 mM KCl and 29.75 mM phosphates). SARS-CoV-2 RBDs
were puriﬁed using HisPur Cobalt resin (Thermo Fisher Scientiﬁc) followed by
buffer exchange into PBS using Amicon centrifugal ﬁlters (MilliporeSigma). S309
Fab binding measurements using surface plasmon resonance were performed on a
Biacore T200 instrument. A CM5 chip with covalently immobilized anti-Avi
polyclonal antibody (GenScript, Cat #: A00674-40) was used for surface capture of
His-Avi tag containing RBDs. Running buffer was HBS-EP + pH 7.4 (Cytiva) and
measurements were performed at 25 °C. Experiments were performed with a 4-fold
dilution series of monomeric S309 Fab: 571, 143, and 36 nM and were run as
single-cycle kinetics. Data were double reference-subtracted and ﬁt to a binding
model using Biacore Evaluation software. The 1:1 binding model was used to
estimate the kinetics parameters. The experiment was performed in triplicate with
technical replicates for each ligand (RBDs). Kinetics values out of instrument’s
limit were omitted. KD values were reported as the average of all replicates.
(b) AZD8895 or AZD1061. Puriﬁed SARS-CoV-2 BA.2 RBD protein was
purchased from AcroBiosystem. SARS-CoV-2 RBD constructs for D614G (residues
334–526), BA.1, and BA.1.1 (residues 319–537) were cloned with an N-terminal
CD33 leader sequence and C-terminal GSSG linker, AviTag, GSSG linker, and
8xHisTag. Recombinant proteins were expressed in FreeStyle 293X or 293 F cells
(Thermo Fisher Scientiﬁc) following transfection with 293fectin (Thermo Fisher
Scientiﬁc) according to manufacturer’s directions. RBD proteins were isolated by
afﬁnity chromatography using a HisTrap column (GE Healthcare), followed by size
exclusion column chromatography (GE Healthcare). AZD8895 and AZD1061
mAbs were isolated from expression supernatants by afﬁnity chromatography
using either MabSelect, protein A or protein G columns (GE Healthcare) and
eluted with 0.1 M glycine at low pH. MAbs were dialyzed into PBS. Fab fragments
were prepared using papain immobilized on agarose resin (Thermo Fisher)
according to manufacturer’s directions, followed by puriﬁcation over either
MabSelect or protein A columns (GE Healthcare/Cytiva).Puriﬁed proteins were
pooled and analyzed by gel electrophoresis (SDS-PAGE) to ensure purity and
appropriate molecular weights, as well as further evaluation by size-exclusion
chromatography coupled to multi-angle light scattering for some proteins.
Kinetic rates (ka, kd, and KD) of AZD1061 and AZD8895 binding to SARS-CoV-2
RBD protein were evaluated by biolayer interferometry using an Octet model
RED384 instrument (FortéBio). Anti-His (HIS1K) biosensors (Pall FortéBio/
Sartorius Part#18–5120) tips were ﬁrst soaked in 1x kinetics buffer for 10 min
followed by a baseline signal measurement in 1x kinetics buffer for 60 sec. His-tagged
SARS-CoV-2 spike RBD diluted in kinetics buffer to 5 μg/mL was loaded onto the
tips for 180 sec. Antigen containing tips were then added to wells containing serial
dilutions of AZD8895 or AZD1061 (at concentrations ranging from 3000 nM to
200 nM). Association and dissociation measurements were made for 300 sec each. All
steps were performed at 30 °C and 1000 rpm shaking. Data were reference subtracted
and ﬁt to a 1:1 binding model using Octet Data Analysis Software 12.0. The ﬁtted
data were plotted with GraphPad Prism software (version 9.0).

Cytokine and Chemokine protein measurements. Lung homogenates were
incubated with Triton-X-100 (1% ﬁnal concentration) for 1 h at room temperature
to inactivate SARS-CoV-2. Homogenates were analyzed for cytokines and chemokines by Eve Technologies Corporation (Calgary, AB, Canada) using their
Mouse Cytokine Array/Chemokine Array 31-Plex (MD31) platform.
Lung pathology. Animals were euthanized before harvest and ﬁxation of tissues.
Brieﬂy, lungs were inﬂated with approximately 1.2 mL of 4% paraformaldehyde
using a 3 mL syringe and catheter inserted into the trachea. Tissues were allowed to
ﬁx for 24 h at room temperature, embedded in parafﬁn, and sections were stained
with hematoxylin and eosin. Slides were scanned using a Hamamatsu NanoZoomer
slide scanning system, and the images were viewed using NDP view software
(ver.1.2.46).
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Statistical analysis. All statistical tests were performed as described in the indicated ﬁgure legends using Prism v8.0 or 9.0. Statistical signiﬁcance was determined
using a one-way ANOVA when comparing three or more groups. When comparing two groups, a Mann-Whitney test was performed. The number of independent experiments performed are indicated in the relevant ﬁgure legends. For
correlation analyses, best-ﬁt lines were calculated using a simple linear regression.
Two-tailed Pearson correlation was used to calculate the R2 and P values indicated
within each panel.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.

Data availability
All data supporting the ﬁndings of this study are available within the paper, in the Source
Data, and from the corresponding author upon request. Source data are provided as
Source Data ﬁles. There are no restrictions in obtaining access to primary data. Models of
mAb complexes were generated from their respective PDB ﬁles with the following
accession codes: COV2–2196 (AZD8895; PDB: 7L7D); COV2–2130 (AZD1061; PDB:
7L7E); S309 (PDB: 6WPS). Source data are provided with this paper.
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